RBR-3kzxsf招募中3 期
A phase III double-bblinded, placebo controlled study of xilonix™ for improving survival in metastatic colorectal cancer.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 —（—）
入选标准
- •Subjects with pathologically confirmed colorectal carcinoma that is metastatic or unresectable and which is refractory to standard therapy; to be considered refractory, a subject must have experienced progression (or intolerance) after treatment with at least all of the following agents: oxaliplatin, irinotecan, flouropyrimidine, and cetuximab or panitumumab if KRAS (retrovirus-associated DNA (desoxinucleic acid) sequences isolated from Kirsten murine sarcoma viruses) wildtype; subjects will not be treated with any radiation, chemotherapy, or investigational agents while enrolled in this protocol; Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2; at least 2 weeks since the last previous cancer treatment including: chemotherapy, radiation therapy, immunotherapy, surgery, hormonal therapy, or targeted biologics and 4 weeks for patients who received treatment immediately prior to the study with anti-IL-1 (anti-interleukin 1) or anti-TNF (tumor necrosis factor) agents; age 18 years or older, male or female subjects; serum potassium and magnesium levels within Central Lab normal limits. Total serum calcium or ionized calcium level must be greater than or equal to the lower limit of normal. Subjects with low potassium, calcium and magnesium levels may be replenished to allow for protocol entry; adequate renal function; adequate hepatic function; adequate bone marrow function; for women of childbearing potential (WOCBP), a negative serum pregnancy test result at screening and monthly thereafter; for women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use adequate methods of contraception, during the treatment period and for at least 1 month after the last dose of study drug; signed and dated institutional review board (IRB)-approved informed consent before any protocol-specific screening procedures are performed; patients enrolled must, in the investigator’s judgment, be healthy enough to stay on the clinical trial for three months.
排除标准
- •Mechanical obstruction that would prevent adequate oral nutritional intake; serious uncontrolled medical disorder, or active infection, that would impair the ability of the patient to receive protocol therapy; uncontrolled or significant cardiovascular disease; dementia or altered mental status that would prohibit the understanding or rendering of informed consent; subjects who have not recovered from the adverse effects of prior therapy at the time of enrollment to grade equal or lower than 1, excluding alopecia and grade 2 neuropathy; immunocompromised subjects; history of hepatitis B or C; history of tuberculosis; receipt of a live (attenuated) vaccine within 1 month prior to screening; subjects with history of hypersensitivity to compounds of similar chemical or biologic composition of xilonix; women who are pregnant or breastfeeding; WOCBP or men whose sexual partners are WOCBP who are unwilling or unable to use an acceptable method of contraception for at least 1 month prior to study entry, for the duration of the study, and for at least 1 month after the last dose of study medication; weight loss higher than 20% in the previous 6 months; history of progressive multifocal leukoencephalopathy or other demyelinating disease; subjects on immunosuppressive therapy, including transplant patients.
研究者
相似试验
进行中（未招募）
不适用
A phase III, duble blinded, placebo controlled study of manteinance Pemetrexed plus Best Supportive Care Immediately following induction treatment for advance non-small cell lung cancer.EUCTR2004-002425-52-ITELI LILLY660
进行中（未招募）
1 期
A study of Xilonix? for Improving Survival in Colorectal CancerMetastatic colorectal cancerMedDRA version: 18.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-005287-10-ESXBiotech Germany GmbH600
进行中（未招募）
1 期
A study of Xilonix™ for patients with Colorectal CancerMetastatic colorectal cancerMedDRA version: 20.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000016864EUCTR2012-005287-10-GBXBiotech Germany GmbH600
进行中（未招募）
1 期
A Study of Xilonix™ for Improving Survival in Colorectal CancerMetastatic colorectal cancerMedDRA version: 20.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000016864EUCTR2012-005287-10-HUXBiotech Germany GmbH600
进行中（未招募）
1 期
A study of Xilonix™ for Improving Survival in Colorectal CancerEUCTR2012-005287-10-DEXBiotech Germany GmbH800